Vascular Dementia Market Set to Hit $2.4B by 2034 as PFE and GILD Eye New Therapies

Key Facts

1The Vascular Dementia market is projected to reach approximately USD 2,399 million by 2034, driven by improved diagnostics and emerging therapies.

Amid a growing focus on neurodegenerative diseases, the vascular dementia market is projected to reach approximately USD 2,399 million by 2034. According to reports, this expansion is primarily driven by improved diagnostic capabilities and the development of emerging therapies by key industry players including PFE and GILD. The increasing prevalence of the condition, coupled with advancements in blood-based biomarkers and recent FDA approvals for related symptoms, are serving as critical catalysts for this long-term growth.

This positive outlook comes as major pharmaceutical firms seek to diversify their pipelines through specialized biotech investments. Per market data, PFE is trading at levels reflecting a transition period, following its reported 2023 annual revenue of $58.5 billion (per Pfizer investor relations), while GILD continues to expand its portfolio beyond its core virology business. Analysts suggest that the successful commercialization of dementia treatments could provide a significant valuation lift for these healthcare giants.

Regarding current market levels, PFE stood at $26.00 (close June 15, 2026), while GILD was priced at $125.45 (close June 17, 2026). Investors should watch for clinical trial updates from emerging competitors like Charsire Biotechnology and ProNeurogen, which could shift market dynamics. Additionally, upcoming economic indicators such as consumer sentiment data will be vital in gauging broader market appetite for high-growth biotech sectors.